Details

Autor(en) / Beteiligte

• Abraham, William T, Dr
• Adamson, Philip B, MD
• Bourge, Robert C, MD
• Aaron, Mark F, MD
• Costanzo, Maria Rosa, MD
• Stevenson, Lynne W, MD
• Strickland, Warren, MD
• Neelagaru, Suresh, MD
• Raval, Nirav, MD
• Krueger, Steven, MD
• Weiner, Stanislav, MD
• Shavelle, David, MD
• Jeffries, Bradley, MD
• Yadav, Jay S, MD

Titel

Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial

Ist Teil von

• The Lancet (British edition), 2011-02, Vol.377 (9766), p.658-666

Ort / Verlag

Kidlington: Elsevier Ltd

Erscheinungsjahr

2011

Quelle

MEDLINE

Beschreibungen/Notizen

• Summary Background Results of previous studies support the hypothesis that implantable haemodynamic monitoring systems might reduce rates of hospitalisation in patients with heart failure. We undertook a single-blind trial to assess this approach. Methods Patients with New York Heart Association (NYHA) class III heart failure, irrespective of the left ventricular ejection fraction, and a previous hospital admission for heart failure were enrolled in 64 centres in the USA. They were randomly assigned by use of a centralised electronic system to management with a wireless implantable haemodynamic monitoring (W-IHM) system (treatment group) or to a control group for at least 6 months. Only patients were masked to their assignment group. In the treatment group, clinicians used daily measurement of pulmonary artery pressures in addition to standard of care versus standard of care alone in the control group. The primary efficacy endpoint was the rate of heart-failure-related hospitalisations at 6 months. The safety endpoints assessed at 6 months were freedom from device-related or system-related complications (DSRC) and freedom from pressure-sensor failures. All analyses were by intention to treat. This trial is registered with ClinicalTrials.gov , number NCT00531661. Findings In 6 months, 84 heart-failure-related hospitalisations were reported in the treatment group (n=270) compared with 120 in the control group (n=280; rate 0·32 vs 0·44, hazard ratio [HR] 0·72, 95% CI 0·60–0·85, p=0·0002). During the entire follow-up (mean 15 months [SD 7]), the treatment group had a 37% reduction in heart-failure-related hospitalisation compared with the control group (158 vs 254, HR 0·63, 95% CI 0·52–0·77; p<0·0001). Eight patients had DSRC and overall freedom from DSRC was 98·6% (97·3–99·4) compared with a prespecified performance criterion of 80% (p<0·0001); and overall freedom from pressure-sensor failures was 100% (99·3–100·0). Interpretation Our results are consistent with, and extend, previous findings by definitively showing a significant and large reduction in hospitalisation for patients with NYHA class III heart failure who were managed with a wireless implantable haemodynamic monitoring system. The addition of information about pulmonary artery pressure to clinical signs and symptoms allows for improved heart failure management. Funding CardioMEMS.